Semaglutide and tirzepatide are cost-effective for obesity at current net prices

Overview Debates Related claims Topics Sources

From the articleInstitute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity

Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity

ICER press release on its evidence report on semaglutide and tirzepatide for obesity, finding current net prices below its health-benefit price benchmarks while noting serious affordability concerns.